Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MiNK Therapeutics ( (INKT) ) has shared an announcement.
On July 15, 2025, MiNK Therapeutics, Inc. entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. to sell shares of its common stock, with a maximum aggregate offering price of $50 million. This agreement, based on a registration statement filed in November 2022, allows the company to raise capital, potentially impacting its financial operations and market positioning.
The most recent analyst rating on (INKT) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.
Spark’s Take on INKT Stock
According to Spark, TipRanks’ AI Analyst, INKT is a Underperform.
MiNK Therapeutics’ overall stock score reflects significant financial challenges and negative market sentiment. The company’s ongoing losses, reliance on external financing, and technical indicators pointing to potential downward momentum weigh heavily on the score. Despite promising clinical advancements and strategic partnerships, financial instability and valuation challenges remain primary concerns.
To see Spark’s full report on INKT stock, click here.
More about MiNK Therapeutics
MiNK Therapeutics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapeutic products.
Average Trading Volume: 889,282
Technical Sentiment Signal: Buy
Current Market Cap: $255.8M
See more data about INKT stock on TipRanks’ Stock Analysis page.